| |
|
|
|
Keystone Symposia, Whistler, British Columbia, Canada
March 18 - 23, 2007
The molecular circuits that are altered in cancers and responsible for malignant transformation are coming into better focus. In some cases cancer cells become ‘addicted’ to these abnormal circuits (networks). Discoveries related to cancer-relevant mutations, and the dependencies they create, will likely accelerate due to cancer resequencing efforts and phenotypic screens with genome-wide si/shRNA libraries. The success of imatinib for both chronic myelogenous leukemia and gastrointestinal stromal tumor and of gefitinib for lung cancers driven by mutant EGFR confirms that drugs targeting oncoproteins can induce tumor regressions with acceptable toxicity. Because of this, a number of agents that inhibit receptor tyrosine kinases, as well as downstream signaling molecules such as those in the Ras-Raf pathway and PI3K-AKT-mTOR pathway, are now being developed. The validity of preclinical models, and the need for robust pharmacodynamic assays, remains a challenge. This meeting will bring together experts and trainees to discuss these challenges in the context of present and future cancer drug targets.
|
|
|
|
|
|
|
|
Organized by:
|
|
William G. Kaelin Jr. and Sara A. Courtneidge |
|
|
Invited Speakers:
|
|
- Robert Abraham, Wyeth
- Stephen Baylin, Johns Hopkins School of Medicine
- Kapil Bhalla, H. Lee Moffitt Cancer Center & Research Center
- Roy Bicknell, University of Birmingham
- Joan Brugge, Harvard Medical School
- Patrick Casey, Duke University Medical Center
- Hans Clevers, Netherlands Institute for Developmental Biology
- Paolo Comoglio, University of Torino Medical School
- Raymond Deshaies, California Institute of Technology
- David Fisher, Dana Farber Cancer Institute
- Todd Golub, Dana Farber Cancer Institute
- Luisa Iruela-Arispe, University of California, Los Angeles
- Eli Keshet, Hebrew University-Hadassah
- A. Look, Dana Farber Cancer Institute
- Matthias Mann, University of Southern Denmark - Odense
- Gordon Mills, University of Texas MD Anderson Cancer Center
- Randall Moon, University of Washington School of Medicine
- Benjamin Neel, Beth Israel Deaconess Medical Center
- Neal Rosen, Memorial Sloan-Kettering Cancer Center
- Judith Sebolt-Leopold, Pfizer Global Research & Development
- Jeffrey Settleman, Harvard Medical School
- Michael Stratton, Wellcome Trust Sanger Institute
- Samuel Wells, Duke University
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
Nov. 20, 2006
|
|
|
|
|
|
|
|
Registration:
|
|
Please see website
|
|
|
E-mail:
|
|
info@keystonesymposia.org
|
|
|
|
|
|
|
|
|